Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths worldwide. Chronic hepatitis C virus (HCV) infection causes induction of several tumors/cancer stem cell (CSC) markers and is known to be a major risk factor for development of HCC. Therefore, drugs that simultaneously target viral replication and CSC properties are needed for a risk-free treatment of advanced stage liver diseases, including HCC. Here, we demonstrated that (Z)-3,5,4′-trimethoxystilbene (Z-TMS) exhibits potent antitumor and anti-HCV activities without exhibiting cytotoxicity to human hepatocytes in vitro or in mice livers. Diethylnitrosamine (DEN)/carbon tetrachloride (CCl4) extensively induced expression of DCLK1 (a CSC marker) in the livers of C57BL/6 mice following hepatic injury. Z-TMS exhibited hepatoprotective effects against DEN/CCl4-induced injury by reducing DCLK1 expression and improving histologic outcomes. The drug caused bundling of DCLK1 with microtubules and blocked cell-cycle progression at G2–M phase in hepatoma cells via downregulation of CDK1, induction of p21cip1/waf1 expression, and inhibition of Akt (Ser473) phosphorylation. Z-TMS also inhibited proliferation of erlotinib-resistant lung adenocarcinoma cells (H1975) bearing the T790M EGFR mutation, most likely by promoting autophagy and nuclear fragmentation. In conclusion, Z-TMS appears to be a unique therapeutic agent targeting HCV and concurrently eliminating cells with neoplastic potential during chronic liver diseases, including HCC. It may also be a valuable drug for targeting drug-resistant carcinomas and cancers of the lungs, pancreas, colon, and intestine, in which DCLK1 is involved in tumorigenesis. Cancer Res; 76(16); 4887–96. ©2016 AACR.

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide with a dismal 5-year survival rate of 11% (1, 2). Chronic infection with hepatitis C virus (HCV) is a major risk factor for the development of HCC (1, 3). HCV patients coinfected with other viruses or with metabolic comorbidity (obesity and diabetes) exhibit faster progression of liver disease and are difficult to treat with standard interferon-based treatment regimens (3). The combinations of direct-acting antiviral (DAA) drugs against three key HCV nonstructural proteins (NS3, NS5A, and NS5B) have shown remarkable efficacy (>90%) for curing the infection (4, 5). However, these drugs are inaccessible to millions of patients and a complete recovery of damaged liver by the HCV treatments alone has not been proven.

The majority of HCC cases are normally diagnosed at late stages, and the use of curative surgery or other treatments are less successful (6, 7). Kinase inhibitors have been shown to increase survival only by a few months or are ineffectual in advanced HCC patients (8). The activation of multiple signaling pathways and enrichment of tumor/cancer stem cells (CSC) within the tumor appear to mediate HCC multidrug resistance (9–11). CSCs represent small subpopulations within a tumor that possess self-renewing capabilities and the ability to differentiate into a heterogeneous lineage within the tumor mass (12–14).

We previously demonstrated a positive correlation between the levels of HCV replication and expression of an array of CSC-associated markers, including doublecortin-like kinase 1 (DCLK1; refs. 15, 16). These changes appear to promote cellular dedifferentiation and the gain of CSC properties in HCV-positive cells. We have further demonstrated that knockdown of DCLK1 results in downregulation of HCV replication, cell migration, and epithelial–mesenchymal transition (EMT) in multiple cancer cell lines and in mouse models (15, 17). There is currently no clear choice for targeting CSCs efficiently (18, 19). DCLK1 is considered to be an important target for the treatment of tumors of the liver, pancreas, and colon. HCV also induces EGFR that facilitates HCV entry into the cells and promotes progression of liver diseases (20, 21). The EGFR inhibitor, erlotinib, has been shown to downregulate HCV RNA levels in a mouse model (20). These observations clearly suggest that cellular kinases (DCLK1 and EGFR) are critical components of HCV-induced chronic liver diseases.

The naturally occurring antioxidant, resveratrol (RVT) has been extensively studied for possible health benefits (22, 23), including anticancer effects (24–26). However, its potential benefits could not be demonstrated in patients with malignancy due to poor absorption and extremely low bioavailability (23, 27). The structurally related analogue (Z)-3,5,4′-trimethoxystilbene (Z-TMS), originally isolated from the bark of Virola elongate, has been shown to inhibit microtubule polymerization, induce G2–M arrest, and inhibit ornithine decarboxylase activity (28, 29). Z-TMS also has long half-life and limited drug clearance when administered intravenously (30, 31). Here, we report mechanism(s) of Z-TMS's antiviral and antitumor activities in several in vitro models and in DEN/CCL4–induced liver injury in C57BL/6 mouse model. Z-TMS exerts its inhibitory effects on tumors by diminishing DCLK1+ cell population, interference with DCLK1-microtubule dynamics, cell-cycle arrest at G2–M phase, promotion of autophagy, and causing nuclear fragmentation. It is considerably effective against erlotinib-resistant T790M-mutant lung carcinoma cells and may evolve as a potential candidate for the treatment of HCV-induced advanced liver diseases, including HCC.

Reagents, antibodies, cells, and cell culture

The non–small cell lung adenocarcinoma cells (NSCLC, H1975) and primary human hepatocytes were purchased from ATCC and BD Biosciences, respectively. All other cells (endogenous) were tested before start of the studies using MycoAlert Kit (Lonza) and were found negative for Mycoplasma. The parent cell line Huh7 and human hepatocytes were recently evaluated (January 14, 2016) for Hantaan virus, LCMV, and Mycoplasma using PCR by IDEXX Bioresearch and were negative for these agents. The characteristics of hepatoma Huh7-derived cell lines (Huh7.5, GS5, and FCA4) have been described previously (15, 16, 32, 33). HCV+DCLK1+ hepatoma cells were generated by transducing G418-resistant FCA4 cells with lentivirus expressing DCLK1 (isoform 1) tagged with RFP at the N-terminus. The cells were cultured as described previously (34). Resveratrol (Sigma) and Z-TMS (Cayman Chemical) were prepared in DMSO and stored at −20°C. EGFR (aa 695–1210) and luciferase assay kits were purchased from Promega. The antibodies were purchased from the following sources: DCLK1 (ab31704), NS5B (35586), actin (ab1801), and Abcam; LC3B (2775), cleaved caspase-3 (Asp175; 9664), and p-Akt (4069), from Cell Signaling Technology; and anti-NS3 antibody (217-A) from Virogen.

Z-TMS treatment of hepatoma cells infected with HCV

The cell culture–generated JFH1 HCV-2a infectious particles (HCVcc) were produced as described previously (35). In brief, JFH1 RNAs were electroporated into Huh7.5 cells and HCVcc particles were determined in cell culture supernatant. Huh7.5 cells were infected with HCVcc at multiplicity of infection of 1 for 48 hours. Subsequently, the HCVcc-infected cells were treated with Z-TMS (1 μmol/L) or equivalent amounts of DMSO in triplicates for 48 hours. The untreated infected cells were considered as positive control, whereas uninfected Huh7.5 cells served as negative control for detection of the HCV RNA by qRT-PCR. The HCV RNA copy numbers per microgram of total RNAs in Z-TMS were calculated and compared with vehicle-treated and -untreated samples. JFH-1/GND RNAs (replication defective JFH1 mutant) were used as negative control. In most of the experiments, HCV-infected cells were serum starved for 4 hours before harvesting. Total RNAs from the HCV replicon–expressing cells were isolated and subjected to RT-PCR as described previously (15).

Western blot analysis, cell survival, and cell proliferation

Cells treated with resveratrol, Z-TMS, or DMSO were washed with PBS, collected, and lysed with mammalian protein extraction reagent (M-PER; Thermo Scientific). Western blots were performed using 30–40 μg of cell lysates (15, 34) and antibodies were diluted as recommended by the manufacturers. Each Western blot analysis was repeated three times. To evaluate target protein to actin ratio, band intensities were calculated using GelQuant software and mean ratios were presented. Cell viability was determined using CellTiter 96 AQueous One Solution (Promega) as recommended by the manufacturer.

H1975 cells were cultured in RPMI1640 media supplemented with 10% FCS. Z-TMS–treated and -untreated H1975 cells in a 96-well culture plate were stained with DRAQ5 and scanned with Operetta (PerkinElmer). Each treatment was done in quadruplets and each well was analyzed for five different fields for the analysis of nuclear fragmentation. The images (average of 5 fields for each well) were analyzed by Columbus software. Wound-healing assay for cell migration was carried out as described previously (34).

Cell-cycle analysis using flow cytometry

Cells treated were with Z-TMS (1 μmol/L) or DMSO for 48 hours, harvested, and washed with PBS. The pelleted cells were resuspended in PBS containing paraformaldehyde (2%) for 1 hour at 4°C, washed twice with ice-cold PBS, resuspended and fixed in 70% ethanol, and incubated overnight at 4°C. The cells were treated with RNase A (200 μg/mL) and propidium iodide (PI, 50 μg/mL; Sigma) for 30 minutes at 37°C in the dark and stored at 4°C until acquisition of the flow cytometry data. The instrument was calibrated with unstained cells and sorted for PI intensity. A total of 10,000 cell events were collected. Flow cytometry data were collected and analyzed using the CELLQuest program (Becton Dickinson).

Kinase activities

EGFR kinase assay was performed using the ADP-Glo kinase assay and recombinant EGFR representing amino acids 695–1210 of the wild type using Promega's protocol. The kinase was treated with 1 μmol/L of Z-TMS or erlotinib in triplicates, and luciferase read-out for the EGFR kinase activities were compared with the untreated control. The experiment was repeated twice.

HCC survival data and IHC of human liver tissues

To evaluate the relationship between DCLK1 expression levels and survival of HCC patients, a Kaplan–Meier plot was generated using the liver HCC (LIHC, total 369 cases) data provided by the TCGA Research Network (http://cancergenome.nih.gov/) using the UCSC Genome Browser. Immunohistochemical staining of liver tissues from patients with HCV and HCC were obtained from the LTCDS (Minneapolis, MN; refs. 15, 34).

Hepatoma xenografts and treatment of C57BL/6 mice with Z-TMS

All mice studies reported here were preapproved (protocols # 12-041 and 15-083) and supervised by the University of Oklahoma Health Sciences Center (OUHSC) Institutional Animal Care and Use Committee, which adheres to the PHS Policy IV.B.3. Athymic nude Balb/c mice were purchased from The Jackson Laboratory and housed in pathogen-free conditions. One million Huh7 cells were washed with PBS three times, resuspended in the same buffer, and injected subcutaneously into the dorsal flanks of 4- to 6-week-old mice as reported previously (34). Tumors were measured with calipers and the volumes were calculated using formula: 0.5 × (length × width2).

Adult immunocompetent C57BL/6 mice (n = 30, 8-week-old, generated by in-house breeding at OUHSC Rodent Barrier Facility) were randomized into 6 groups (5 mice/group). Groups 1 through 3 received two intraperitoneal injections of diethylnitrosamine [DEN, 25 mg/kg body weight (BW), one injection per week] followed by twice-weekly injections of CCl4 (1 mL/kg BW) for the next 7 weeks. Except group 1, groups 2 and 3 were also treated with 20 and 40 mg/kg BW of Z-TMS dissolved in DMSO, respectively. Group 4 received only Z-TMS (40 mg/kg BW) to determine its possible toxicity. Groups 5 and 6 served as DMSO and untreated controls, respectively, during the same period. At the termination of the experiments, all the animals were euthanized and subjected to necropsy for collection and analysis of blood or tissues of different organs.

Statistical analysis

All experiments were performed in biological replicates of at least three and repeated to confirm the results. The graphs were presented as mean ± SD. The P values were calculated using the Student t test. Results with P ≤ 0.05 were considered statistically significant.

Z-TMS is a potent HCV inhibitor

Published reports suggest potential benefits of resveratrol (3,5,4′-trihydroxy-trans-stilbene, RVT) and its analogues on human health (reviewed in refs. 36, 37). We initially tested the anti-HCV activities of RVT and its natural analogue Z-TMS in hepatoma cell lines (GS5 and FCA4) expressing HCV-1b subgenomic replicons (16, 34). The results suggested that Z-TMS is nearly 100 times more potent in downregulating the levels of HCV NS5B polymerase, which is now considered a core target of direct antiviral therapy (results not shown). Next, FCA4 cells were treated with varying amounts (0, 0.05, 0.1, 0.5, 1.0, and 2.5 μmol/L) of Z-TMS or equivalent amounts of DMSO for 48 hours. The total lysates prepared from drug-treated and -untreated cells were analyzed for NS5B and actin (loading control) levels. The data suggest that Z-TMS inhibits NS5B expression in a dose-dependent manner (Fig. 1A, lanes 2–6). Similar results were obtained with GS5 cells (not shown). The DMSO solvent control had no inhibitory effect on the NS5B levels (lanes 7–11) as compared with the untreated control (lane 1). Under these conditions (0.1–1.0 μmol/L Z-TMS for 48-hour treatment), FCA4 cells as well as normal human hepatocytes remained fully viable (Fig. 1B and C).

To examine whether Z-TMS inhibits HCV replication in an HCV infection model, Huh7.5 cells were infected with tissue culture–generated JFH1 viruses (HCVcc) for 48 hours to allow replication of the viral RNA. The infected cells were then treated with 1 μmol/L of Z-TMS or vehicle for 48 hours. Total RNAs isolated from these cells were subjected to qRT-PCR to determine the levels of HCV replication. As expected, the JFH1 RNA copy number was drastically reduced (∼10 times) by Z-TMS treatment as compared with the DMSO-treated or -untreated cells (Fig. 1D). The results were fully corroborated by the dramatic reduction in NS3 level (Fig. 1E, lane 3) as compared with the controls (lanes 2 and 4).

Z-TMS disrupts DCLK1-microtubule dynamics

Microtubules are highly dynamic structures whose regulations are critical for HCV replication, cell division, cell migration, and cell polarity. The CSC marker DCLK1 associates with microtubules and stimulates polymerization of tubulins. We have previously shown that DCLK1 is overexpressed in liver tissues derived from patients with cirrhosis and HCC. Its expression is also correlated with activation of inflammatory and protumorigenic signals as well as hepatoma cell migration (34). These observations led us to investigate the significance of DCLK1 overexpression in patient survival and effects of Z-TMS on DCLK1 interaction with microtubules or microtubule dynamic instability. As shown in Fig. 2A, DCLK1 is overexpressed in liver tissues of HCV-positive patients with cirrhosis and HCC but not in normal liver. The Kaplan–Meier plot suggests that the 5-year survival rate is approximately reduced by three times in HCC patients (n = 369) with hepatic DCLK1 overexpression (Fig. 2B, red and black lines) as compared with the patients with low DCLK1 levels (green line). In a mouse tumor xenograft model described previously (34), large tumors (average size of 4–4.5 cm3) derived from Huh7 cells exhibited extensive staining for human DCLK1 except the one that was smaller in size (0.65 cm3; Fig. 2C). Because of DCLK1′s important roles in microtubule dynamics, HCV replication and tumor growth in addition to the ability of HCV+DCLK1+ hepatoma cells to form spheroids (15, 16), we examined the effects of Z-TMS on HCV+DCLK1+ cells. These cells were isolated from FCA4 cells coexpressing recombinant RFP-DCLK1 and HCV subgenomic replicon by FACS method. As shown in Fig. 2D, expression of HCV NS5B polymerase in HCV+DCLK1+ hepatoma cells was significantly reduced by 1 μmol/L of Z-TMS treatment (lane 3) as compared with controls (lanes 1 and 2). Z-TMS treatment also caused significant inhibition in the proliferative potential of these cells (Fig. 2E). We carried out confocal immunofluorescence microscopy to determine localization of DCLK1 with microtubule in these cells after Z-TMS treatment. The results revealed that Z-TMS induces bundling of microtubules and speckle-like structures of DCLK1–microtubule complexes (Fig. 2F, bottom). However, the untreated and DMSO-treated cells exhibit normal distribution of DCLK1 (red) and tubulin (green) or their complexes (yellow). Collectively, these results indicate a direct relationship of DCLK1 with the survival of HCC patients and possibility of targeting HCV-positive DCLK1-overexpressing hepatoma cells by Z-TMS.

We used a 3D magnetic levitation method (38) to culture GS5 cells as visible cell spheroids/aggregates (Fig. 3A). The levels of NS5A-GFP green fluorescence indicated continued HCV replication in the spheroid-like cultures (Fig. 3A, inset). Immunohistochemical staining of these aggregates revealed different cell phenotypes. Although large cells displayed extensive CK19 expression (circulating tumor cell marker) and cell-to-cell contacts, a low number of unique small cells were DCLK1 positive. This observation clearly suggests heterogeneous cell phenotypes in the spheroids. Z-TMS successfully inhibited growth of this cellular mass (Fig. 3B).

Z-TMS causes G2–M cell-cycle arrest, inhibition of Akt phosphorylation, and upregulation of p21Cip1/Waf1 in hepatoma cells

GS5 cells, which express a NS5A-GFP chimeric protein encoded by HCV-1b subgenomic RNAs, and Huh 7.5 cells were treated with 1 μmol/L of Z-TMS for 48 hours and stained with PI for cell-cycle analysis. The results clearly suggest that most GS5 cells and Huh7.5 parent cells were stalled in the G2–M phase (>90%) with a concomitant reduction in the G1 and S-phases (Fig. 4A). However, DMSO-treated and untreated cells showed similar cell-cycle distribution. The result shows that the observed change in cell cycle was induced by Z-TMS and not by the DMSO (solvent). Similar Z-TMS effects were observed for other hepatoma cell lines (Huh7 and FCA4, not shown). Next, total lysates of the drug-treated and -untreated cells were subjected to Western blot analysis for detection of proteins involved in cell-cycle checkpoints. Z-TMS treatment caused downregulation of total cyclin-dependent kinase 1 (CDK1) with a concomitant induction of p21Cip1/Waf1 expression (Fig. 4B, lane 3), which is a potent inhibitor of CDK1 and CDK2. Also, p21Cip1/Waf1 mediates growth arrest and cellular senescence. Activation of Akt overcomes a G2–M cell-cycle checkpoint induced by DNA damage (39). Therefore, successful blockage of cancer cells at G2–M phase should also be accompanied by the downregulation of Akt. Treatment of GS5 cells with Z-TMS (1 μmol/L) resulted in significant downregulation of Akt (Ser473) phosphorylation without affecting total Akt level (Fig. 4C, lane 3). Taken together, Z-TMS appears to induce G2–M cell-cycle arrest by induction of p21Cip1/Waf1 and downregulation of Akt signaling.

Broad-spectrum antitumor activities of Z-TMS

Because Z-TMS inhibits Akt activation, the status and function of its upstream regulator EGFR) was examined. Our interest in EGFR investigation stems in part from the observation that erlotinib, an EGFR inhibitor, diminishes HCV entry into cells and reduces HCV replication in a mouse model (20). Because of the lack of an EGFR-mutant hepatoma model, we used a well-characterized erlotinib-resistant lung adenocarcinoma (NSCLC) H1975 cells that contains the T790M gatekeeper mutation in EGFR to determine the effect of Z-TMS on these cells. As shown in Fig. 5A, Z-TMS significantly reduced survival of H1975 cells in the 0.1 μmol/L to 1.0 μmol/L range within 48 hours, whereas erlotinib failed to reduce cell survival even though it was fully active against the wild-type EGFR kinase domain (aa 695–1210; Fig. 5A and B). The luciferase-based EGFR activity assay suggests that erlotinib efficiently inhibited (90%) the kinase activities, whereas Z-TMS failed to exhibit strong inhibition in spite of reducing H1975 survival. Confocal immunostaining clearly revealed that only Z-TMS but not erlotinib induced microtubule bundling (Fig. 5C, middle). Unlike the intense colocalization of DCLK1 with microtubules in DCLK1-overexpressing hepatoma cells (Fig. 2F), we observed mostly punctate staining of DCLK1 in H1975 probably due to alternatively spliced or post-translationally modified forms that do not preferentially bind microtubules (Fig. 5C).

To understand the mechanism of Z-TMS–induced cell death, H1975 cells were cultured in a 96-well plate and treated with Z-TMS (1 μmol/L) in quadruplets. After fixing the cells, nuclei were stained and the extent of nuclear fragmentation was assessed. The data suggest that Z-TMS induces nuclear fragmentation in nearly 70% to 80% cells as compared with the untreated or DMSO or cisplatin (50 μmol/L) treated controls (Fig. 5D). Total lysates of H1975 cells treated with the drugs as described above showed activation of autophagy markers, LC3B-I and LC3B-II proteins in Z-TMS–treated cell lysate (Fig. 5E, lane 3), which were much higher than the corresponding controls (lanes 1, 2 and 4). Similar Western blot analysis suggested that only cisplatin, but not Z-TMS, induces cleaved caspase-3 (Asp175), which marks cell death by apoptosis (Fig. 5F). Thus, Z-TMS appears to induce H1975 cell death by autophagy and nuclear fragmentation.

Z-TMS protects liver from DEN/CCl4-induced injury, reduces DCLK1+ cell number at injury sites, and promotes hepatic recovery

The scheduled administration of DEN (one injection) followed by twice-weekly injections of carbon tetrachloride (CCl4) induces liver injury that further progresses to fibrosis and HCC within 8 to 10 months (40–42). We treated immunocompetent C57BL/6 mice with two DEN (25 mg/kg BW) injections once a week followed by administration of CCl4 (1 mL/kg BW) alone or with Z-TMS (20 or 40 mg/kg BW) twice per week for 7 weeks (groups 1 through 3 in Table 1; Fig. 6A). As expected, the DEN/CCl4–treated mice developed liver injury characterized by histologic perturbations and appearance of nonepithelial cells in the parenchyma (Fig. 6A, extreme left panels). These regions also exhibited unusually high numbers of DCLK1+ cells with intense staining in epithelial and nonepithelial compartments at the injury sites (only two liver sections from different mice of the same group are shown in top and bottom). This observation suggests that DEN/CCl4–led injury significantly induces DCLK1 expression in liver (highlighted in Fig. 6B). The untreated control (normal) mice livers were largely negative for DCLK1 stain or occasionally revealed a fewer DCLK1+ cells within portal triads (extreme right). The mice treated with Z-TMS (groups 2 and 3), which were simultaneously receiving DEN/CCL4 doses, exhibited improved histologic appearance with significantly reduced number of DCLK1+ cells as compared with group 1 (DEN/CCl4 treated, Fig. 6A). Both histologic and liver function panel (ALB, ALT, AST, ALKP, and TBIL in Table 1) data clearly suggest that Z-TMS alone (group 4) does not exhibit hepatotoxicity under these treatment conditions. Instead, Z-TMS successfully protected the liver from toxic agents and improved injury most likely by eliminating or suppressing DCLK1+ cells. Mice in any group did not lose their body weight.

Viral hepatitis, steatohepatitis, and metabolic disorders substantially contribute to the development of cirrhosis and primary HCC. End-stage liver disease due to chronic HCV infection is expected to remain a major health care issue in most countries partly due to lack of effective treatment options or inaccessibility to newly discovered drugs. Current HCC antineoplastic drugs, sorafenib alone or in combination with other drugs, cause considerable toxicity and only improve median overall survival by 3 months. Here, we have reported novel properties of Z-TMS that exerts its antiviral and antitumor activities by interference with the CSC marker DCLK1, microtubule dynamics, induction of autophagy, G2–M arrest and nuclear fragmentation. The combined effects reflect in vitro efficacy of Z-TMS against the drug-resistant tumor cells such as NSCLC. Z-TMS also promotes hepatic recovery from extensive DEN (genotoxic)/CCl4 (hepatotoxic) induced liver injury in immunocompetent C57BL mice. Thus, Z-TMS may potentially block initiation and progression of HCC by targeting DCLK1. This notion is also supported by our observation that DCLK1 downregulation results in reduction of hepatoma-like tumor growth (43). Although Z-TMS at doses 20 and 40 mg/Kg BW did not exhibit hepatic toxicity, 20% mice showed complications in gastrointestinal emptying. These observations warrant us for optimizing drug dosages and duration of treatment to gain its maximum health benefits.

Using subgenomic replicons and full-length JFH1 infection models of HCV, we have demonstrated the efficacy of Z-TMS against widely prevalent HCV genotypes 1 and 2. The magnetic levitation experiments revealed that growth of HCV-expressing spheroids/aggregates could also be effectively targeted by Z-TMS. The heterogeneity of this cellular mass and cell-to-cell contacts in the spheroids were revealed by immunohistochemical staining showing membranous CK19. It further showed expected DCLK1+ subpopulations (usually 1%–2% of total GS5 cells; ref. 15). Our in vivo experiments suggest that Z-TMS can diminish the DCLK1+ population in injured livers. Because DCLK1 appears to be involved in HCV replication and hepatic malignancy (15, 16, 43), it is likely that Z-TMS will be able to eliminate HCV-expressing cancer stem–like cells to prevent progression of liver diseases.

Although normal liver parenchyma lacks detectable DCLK1 expression, DCLK1 expression and number of DCLK1+ cells are increased significantly in the stroma, regenerative cirrhotic nodules, and HCC. Z-TMS clearly targeted DCLK1-microtubule dynamics that promotes HCV replication, cell migration, and cell-cycle progression. Microtubule-stabilizing drugs (paclitaxel and docetaxel) and destabilizing drugs (vinblastine and nocodazole) have been extensively used for the treatment of cancer (44, 45). A few of these drugs have also been shown to hamper movement of the HCV replication complexes required for viral replication (46). By sequestering DCLK1 with bundled microtubules, Z-TMS will block survival, proliferation, and division of DCLK1+ CSC cells.

Cancer/tumor stem cells (CSC) are key contributors of drug resistance, metastasis, and recurrence of tumors. At present, effectively targeting CSCs for treatment is challenging (18, 19). We previously demonstrated that HCV induces several CSC markers (CD133, Lgr5, and c-Myc), including DCLK1 (47, 48). Our current data revealed that DCLK1 overexpression in HCC-positive patients considerably reduces survival rate. Z-TMS causes sequestration of DCLK1 with microtubule bundles accompanied by a dramatic decrease in the NS5B polymerase level in HCV+DCLK1+ hepatoma cells. Z-TMS appears to be effective against DCLK1-positive CSCs. DCLK1 has been shown to play important roles in the development of intestinal polyps, intestinal response to radiation injury, cell survival, and control of metastasis. In addition, we have shown that DCLK1 positively regulates HCV replication in knockdown and overexpression systems. Thus, Z-TMS–targeted elimination of HCV-positive cells bearing CSCs footprints is likely to benefit patients with advanced liver diseases, including HCC.

The molecular mechanisms of Z-TMS's antiproliferative effects were also studied. We observed that Z-TMS treatment resulted in G2–M arrest (95%) of hepatoma cells independent of HCV within 48 hours. Cell-cycle progression is orchestrated by cyclins and cyclin-dependent kinases (CDK). CyclinB1/CDK1 complex specifically regulates cell entry into mitosis, and enhances mitochondrial respiration and ATP generation for G2–M transition. In accordance with these observations, we observed a considerable decrease in total CDK1 and a concomitant increase in the cell-cycle inhibitor, p21Cip/Waf1, following Z-TMS treatment. The observed p21Cip/Waf1 induction after Z-TMS treatments resulted in inhibition of CDK1 activities and cell-cycle arrest. Akt activation downstream of the PI3K/Akt/mTOR pathway regulates multiple cellular processes such as cell growth, CSC survival, metabolism, angiogenesis, and proliferation. Phosphorylation of Akt at Ser473 by mTORC2 is required for its hyperactivation and stabilization of its active conformation. We observed a considerable inhibition of Akt (Ser473) phosphorylation following Z-TMS treatment. In addition, Z-TMS induced autophagy that was accompanied by nuclear fragmentation. These properties are especially desirable for the treatment of hard-to-treat drug-resistant cancers.

In conclusion, the results presented here collectively support Z-TMS as a unique potent anti-HCV and antitumor drug that exerts its effects by targeting multiple pathways. Z-TMS significantly reduces DCLK1+ CSC populations during hepatic injury, interferes with DCLK1-microtubule dynamics, arrests cell cycle at G2–M phase, promotes autophagy, and causes nuclear fragmentation. Thus, Z-TMS potentially overrides NSCLC resistance to erlotinib because of its unique mechanisms of action.

S. Sureban has ownership interest (including patents) in patents. M.S. Bronze is a consultant/advisory board member for Genentech/Roche. C.W. Houchen has ownership interest (including patents) and is a consultant/advisory board member for COARE Biotechnology Inc. No potential conflicts of interest were disclosed by the other authors.

Conception and design: C.B. Nguyen, H. Kotturi, G. Waris, A. Mohammed, C.W. Houchen, N. Ali

Development of methodology: C.B. Nguyen, H. Kotturi, A. Mohammed, C.W. Houchen, N. Ali

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): C.B. Nguyen, H. Kotturi, G. Waris, A. Mohammed, N. Ali

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): C.B. Nguyen, H. Kotturi, G. Waris, A. Mohammed, P. Chandrakesan, S. Sureban, D. Qu, C.V. Rao, N. Ali

Writing, review, and/or revision of the manuscript: C.B. Nguyen, H. Kotturi, A. Mohammed, M.S. Bronze, C.W. Houchen, N. Ali

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): H. Kotturi, R. May, N. Weygant, D. Qu, C.V. Rao, D.N. Dhanasekaran, N. Ali

Study supervision: H. Kotturi, A. Mohammed, C.W. Houchen, N. Ali

The authors are thankful to the Liver Tissue Cell Distribution System, (Minneapolis, MN). We thank Stephenson Cancer Center Pathology Core Laboratory for immunohistochemistry.

This work was partially supported by VA Merit Award and the Frances and Malcolm Robinson Endowed Chair (C.W. Houchen). N. Ali is partially supported by an Institutional Development Award (IDeA) from NIH (1P20GM103639NIH) and COMAA Research Fund Seed Grant (OUHSC).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1.
Yang
JD
,
Roberts
LR
. 
Hepatocellular carcinoma: a global view
.
Nat Rev Gastroenterol Hepatol
2010
;
7
:
448
58
.
2.
Bartosch
B
,
Thimme
R
,
Blum
HE
,
Zoulim
F
. 
Hepatitis C virus-induced hepatocarcinogenesis
.
J Hepatol
2009
;
51
:
810
20
.
3.
El-Serag
HB
. 
Epidemiology of viral hepatitis and hepatocellular carcinoma
.
Gastroenterology
2012
;
142
:
1264
73
.
4.
Afdhal
N
,
Reddy
KR
,
Nelson
DR
,
Lawitz
E
,
Gordon
SC
,
Schiff
E
, et al
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection
.
N Engl J Med
2014
;
370
:
1483
93
.
5.
Afdhal
N
,
Zeuzem
S
,
Kwo
P
,
Chojkier
M
,
Gitlin
N
,
Puoti
M
, et al
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection
.
N Engl J Med
2014
;
370
:
1889
98
.
6.
Bertino
G
,
Demma
S
,
Ardiri
A
,
Proiti
M
,
Gruttadauria
S
,
Toro
A
, et al
Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies
.
BioMed Res Int
2014
;
2014
:
203693
.
7.
Padhya
KT
,
Marrero
JA
,
Singal
AG
. 
Recent advances in the treatment of hepatocellular carcinoma
.
Curr Opin Gastroenterol
2013
;
29
:
285
92
.
8.
Llovet
JM
,
Ricci
S
,
Mazzaferro
V
,
Hilgard
P
,
Gane
E
,
Blanc
JF
, et al
Sorafenib in advanced hepatocellular carcinoma
.
N Engl J Med
2008
;
359
:
378
90
.
9.
Gauthier
A
,
Ho
M
. 
Role of sorafenib in the treatment of advanced hepatocellular carcinoma: an update
.
Hepatol Res
2013
;
43
:
147
54
.
10.
Chow
AK
,
Ng
L
,
Lam
CS
,
Wong
SK
,
Wan
TM
,
Cheng
NS
, et al
The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance
.
PLoS ONE
2013
;
8
:
e78675
.
11.
Chen
KF
,
Chen
HL
,
Tai
WT
,
Feng
WC
,
Hsu
CH
,
Chen
PJ
, et al
Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells
.
J Pharmacol Exp Ther
2011
;
337
:
155
61
.
12.
Kasai
T
,
Chen
L
,
Mizutani
A
,
Kudoh
T
,
Murakami
H
,
Fu
L
, et al
Cancer stem cells converted from pluripotent stem cells and the cancerous niche
.
J Stem Cells Regen Med
2014
;
10
:
2
7
.
13.
Majumdar
A
,
Curley
SA
,
Wu
X
,
Brown
P
,
Hwang
JP
,
Shetty
K
, et al
Hepatic stem cells and transforming growth factor beta in hepatocellular carcinoma
.
Nat Rev Gastroenterol Hepatol
2012
;
9
:
530
8
.
14.
Yamashita
T
,
Wang
XW
. 
Cancer stem cells in the development of liver cancer
.
J Clin Invest
2013
;
123
:
1911
8
.
15.
Ali
N
,
Allam
H
,
May
R
,
Sureban
SM
,
Bronze
MS
,
Bader
T
, et al
Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor xenografts
.
J Virol
2011
;
85
:
12292
303
.
16.
Ali
N
,
Allam
H
,
Bader
T
,
May
R
,
Basalingappa
KM
,
Berry
WL
, et al
Fluvastatin interferes with hepatitis C virus replication via microtubule bundling and a doublecortin-like kinase-mediated mechanism
.
PLoS ONE
2013
;
8
:
e80304
.
17.
Weygant
N
,
Qu
D
,
Berry
WL
,
May
R
,
Chandrakesan
P
,
Owen
DB
, et al
Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1
.
Mol Cancer
2014
;
13
:
103
.
18.
Jung
Y
,
Kim
WY
. 
Cancer stem cell targeting: are we there yet?
Arch Pharm Res
2015
;
38
:
414
22
.
19.
Zhou
BB
,
Zhang
H
,
Damelin
M
,
Geles
KG
,
Grindley
JC
,
Dirks
PB
. 
Tumour-initiating cells: challenges and opportunities for anticancer drug discovery
.
Nat Rev Drug Discov
2009
;
8
:
806
23
.
20.
Lupberger
J
,
Zeisel
MB
,
Xiao
F
,
Thumann
C
,
Fofana
I
,
Zona
L
, et al
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy
.
Nat Med
2011
;
17
:
589
95
.
21.
Diao
J
,
Pantua
H
,
Ngu
H
,
Komuves
L
,
Diehl
L
,
Schaefer
G
, et al
Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry
.
J Virol
2012
;
86
:
10935
49
.
22.
Tresguerres
IF
,
Tamimi
F
,
Eimar
H
,
Barralet
J
,
Torres
J
,
Blanco
L
, et al
Resveratrol as anti-aging therapy for age-related bone loss
.
Rejuvenation Res
2014
;
17
:
439
45
.
23.
Singh
CK
,
George
J
,
Ahmad
N
. 
Resveratrol-based combinatorial strategies for cancer management
.
Ann N Y Acad Sci
2013
;
1290
:
113
21
.
24.
Li
J
,
Chong
T
,
Wang
Z
,
Chen
H
,
Li
H
,
Cao
J
, et al
A novel anticancer effect of resveratrol: reversal of epithelialmesenchymal transition in prostate cancer cells
.
Mol Med Rep
2014
;
10
:
1717
24
.
25.
Liu
B
,
Zhou
Z
,
Zhou
W
,
Liu
J
,
Zhang
Q
,
Xia
J
, et al
Resveratrol inhibits proliferation in human colorectal carcinoma cells by inducing G1/Sphase cell cycle arrest and apoptosis through caspase/cyclinCDK pathways
.
Mol Med Rep
2014
;
10
:
1697
702
.
26.
Kao
CL
,
Huang
PI
,
Tsai
PH
,
Tsai
ML
,
Lo
JF
,
Lee
YY
, et al
Resveratrol-induced apoptosis and increased radiosensitivity in CD133-positive cells derived from atypical teratoid/rhabdoid tumor
.
Int J Radiat Oncol Biol Phys
2009
;
74
:
219
28
.
27.
Borriello
A
,
Bencivenga
D
,
Caldarelli
I
,
Tramontano
A
,
Borgia
A
,
Zappia
V
, et al
Resveratrol: from basic studies to bedside
.
Cancer Treat Res
2014
;
159
:
167
84
.
28.
MacRae
WD
,
Towers
GH
. 
An ethnopharmacological examination of Virola elongata bark: a South American arrow poison
.
J Ethnopharmacol
1984
;
12
:
75
92
.
29.
Schneider
Y
,
Chabert
P
,
Stutzmann
J
,
Coelho
D
,
Fougerousse
A
,
Gosse
F
, et al
Resveratrol analog (Z)-3,5,4′-trimethoxystilbene is a potent anti-mitotic drug inhibiting tubulin polymerization
.
Int J Cancer
2003
;
107
:
189
96
.
30.
Chabert
P
,
Fougerousse
A
,
Brouillard
R
. 
Anti-mitotic properties of resveratrol analog (Z)-3,5,4′-trimethoxystilbene
.
BioFactors
2006
;
27
:
37
46
.
31.
Lin
HS
,
Zhang
W
,
Go
ML
,
Choo
QY
,
Ho
PC
. 
Determination of Z-3,5,4′-trimethoxystilbene in rat plasma by a simple HPLC method: application in a pre-clinical pharmacokinetic study
.
J Pharm Biomed Anal
2010
;
53
:
693
7
.
32.
Guo
JT
,
Bichko
VV
,
Seeger
C
. 
Effect of alpha interferon on the hepatitis C virus replicon
.
J Virol
2001
;
75
:
8516
23
.
33.
Nelson
HB
,
Tang
H
. 
Effect of cell growth on hepatitis C virus (HCV) replication and a mechanism of cell confluence-based inhibition of HCV RNA and protein expression
.
J Virol
2006
;
80
:
1181
90
.
34.
Ali
N
,
Chandrakesan
P
,
Nguyen
CB
,
Husain
S
,
Gillaspy
AF
,
Huycke
M
, et al
Inflammatory and oncogenic roles of a tumor stem cell marker doublecortin-like kinase (DCLK1) in virus-induced chronic liver diseases
.
Oncotarget
2015
;
6
:
20327
44
.
35.
Iqbal
J
,
McRae
S
,
Banaudha
K
,
Mai
T
,
Waris
G
. 
Mechanism of hepatitis C virus (HCV)-induced osteopontin and its role in epithelial to mesenchymal transition of hepatocytes
.
J Biol Chem
2013
;
288
:
36994
7009
.
36.
Novelle
MG
,
Wahl
D
,
Dieguez
C
,
Bernier
M
,
de Cabo
R
. 
Resveratrol supplementation: where are we now and where should we go?
Ageing Res Rev
2015
;
21C
:
1
15
.
37.
Baur
JA
,
Pearson
KJ
,
Price
NL
,
Jamieson
HA
,
Lerin
C
,
Kalra
A
, et al
Resveratrol improves health and survival of mice on a high-calorie diet
.
Nature
2006
;
444
:
337
42
.
38.
Souza
GR
,
Molina
JR
,
Raphael
RM
,
Ozawa
MG
,
Stark
DJ
,
Levin
CS
, et al
Three-dimensional tissue culture based on magnetic cell levitation
.
Nat Nanotechnol
2010
;
5
:
291
6
.
39.
Kandel
ES
,
Skeen
J
,
Majewski
N
,
Di Cristofano
A
,
Pandolfi
PP
,
Feliciano
CS
, et al
Activation of Akt/protein kinase B overcomes a G(2)/m cell-cycle checkpoint induced by DNA damage
.
Mol Cell Biol
2002
;
22
:
7831
41
.
40.
Uehara
T
,
Ainslie
GR
,
Kutanzi
K
,
Pogribny
IP
,
Muskhelishvili
L
,
Izawa
T
, et al
Molecular mechanisms of fibrosis-associated promotion of liver carcinogenesis
.
Toxicol Sci
2013
;
132
:
53
63
.
41.
Dapito
DH
,
Mencin
A
,
Gwak
GY
,
Pradere
JP
,
Jang
MK
,
Mederacke
I
, et al
Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4
.
Cancer Cell
2012
;
21
:
504
16
.
42.
Caviglia
JM
,
Schwabe
RF
. 
Mouse models of liver cancer
.
Methods Mol Biol
2015
;
1267
:
165
83
.
43.
Sureban
SM
,
Madhoun
MF
,
May
R
,
Qu
D
,
Ali
N
,
Fazili
J
, et al
Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism
.
Oncotarget
2015
;
6
:
37200
15
.
44.
Yang
H
,
Ganguly
A
,
Cabral
F
. 
Inhibition of cell migration and cell division correlates with distinct effects of microtubule inhibiting drugs
.
J Biol Chem
2010
;
285
:
32242
50
.
45.
Kavallaris
M
. 
Microtubules and resistance to tubulin-binding agents
.
Nat Rev Cancer
2010
;
10
:
194
204
.
46.
Lai
CK
,
Jeng
KS
,
Machida
K
,
Lai
MM
. 
Association of hepatitis C virus replication complexes with microtubules and actin filaments is dependent on the interaction of NS3 and NS5A
.
J Virol
2008
;
82
:
8838
48
.
47.
Lin
PT
,
Gleeson
JG
,
Corbo
JC
,
Flanagan
L
,
Walsh
CA
. 
DCAMKL1 encodes a protein kinase with homology to doublecortin that regulates microtubule polymerization
.
J Neurosci
2000
;
20
:
9152
61
.
48.
Kim
MH
,
Cierpicki
T
,
Derewenda
U
,
Krowarsch
D
,
Feng
Y
,
Devedjiev
Y
, et al
The DCX-domain tandems of doublecortin and doublecortin-like kinase
.
Nat Struct Biol
2003
;
10
:
324
33
.